Beijing GoBroad Hospital is a research hospital with a focus on diagnosing and treating challenging and critical cases, conducting clinical research, and strategically transforming the industries of biomedicine. It has always been committed to promoting the innovation and progress of medical technology. In order to promote the development of medical technology, promote the marketing of new radiopharmaceuticals, and meet the diagnosis and treatment needs of patients, the hospital has added a new radionuclide project on the basis of the original Class B non-sealed radioactive material workplace, successfully passed the examination of the environmental protection and health administrative departments, and officially obtained the qualification for clinical application of ¹⁷⁷Lu radionuclide therapy. The new ¹⁷⁷Lu radionuclide project is an important exploration and practice of the hospital in the field of nuclear medicine.

¹⁷⁷Lu radionuclide therapy is a new approach of tumor treatment, which gets radionuclides to be involved in human metabolism and accumulate in specific tissues to precisely kill diseased cells. This treatment method is highly selective, and can achieve precise internal radiation therapy of tumor lesions, improve efficacy and reduce side effects. Beijing GoBroad Hospital has 4 radionuclide treatment wards, and can treat up to 200 patients per year.

After decades of development from early ¹³¹I, ¹²⁵I and ⁸⁹Sr to later ⁹⁰Y, ²²³Ra, ¹⁷⁷Lu, and ²²⁵Ac, radionuclide therapy has been widely used in the treatment of a variety of malignant tumors. Globally, radionuclide therapy is booming. The US FDA has approved ¹⁷⁷Lu-Dotatate for the treatment of gastroenteropancreatic neuroendocrine tumors and ¹⁷⁷Lu-PSMA for the treatment of metastatic castration-resistant prostate cancer. In China, the National Medical Products Administration has also approved radium chloride (²²³Ra) and ⁹⁰Y-microsphere injection for the treatment of specific cancers.

With the rapid development of integrated technology of molecular biology and radionuclide diagnosis and treatment, the application of radionuclide therapy has been expanded to the treatment of a variety of malignant tumors, and has demonstrated favorable efficacy and safety. A number of radionuclide drugs are under the Phase 2-3 clinical studies, covering more than 10 kinds of malignant tumors. Radionuclide therapy is expected to become another important treatment after surgery, chemotherapy, radiotherapy, interventional therapy and immunotherapy.

In order to promote the development of radionuclide diagnosis and treatment technology, 8 authorities including China Atomic Energy Authority have jointly issued the Medium and Long-term Development Plan for Medical Isotopes (2021-2035). In this context, Beijing GoBroad Hospital has upgraded its facilities for clinical application of radionuclide, and strengthened the collaboration between scientific research and clinical teams so as to contribute to the development of radionuclide diagnosis and treatment technology.